BUCHANG PHARMA announced that its wholly-owned subsidiary, Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Oseltamivir Phosphate Capsules issued by the National Medical Products Administration. This drug is mainly used for the treatment of influenza A and B in adults and children aged 1 year and older, as well as for the prevention of influenza A and B in adults and adolescents aged 13 years and older. The annual sales of physical pharmacies in Chinese cities from 2022 to 2024 are projected to be 152 million yuan, 824 million yuan, and 776 million yuan, respectively. As of the announcement date, the company has invested approximately 12.9612 million yuan in research and development expenses for this project
